Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Chin J Integr Med ; 29(2): 146-154, 2023 Feb.
Article in English | MEDLINE | ID: mdl-35799086

ABSTRACT

OBJECTIVE: To determine whether resveratrol (Res) can correct osteoporosis induced in a rat model of male hypogonadism. METHODS: Thirty-two rats were randomly divided into 4 groups, 8 in each group; 1) a control sham group: underwent a similar surgical procedure for induction of orchiectomy (ORCD) without ligation of any arteries or veins or removal of the testis and epididymis; 2) a control + Res-treated group (Con+Res): underwent sham surgery similar to the control, but was then treated with Res, as described below; 3) an ORCD-induced group: bilateral ORCD surgery as described above, and 4) a ORCD+Res-treated group: bilateral ORCD surgery followed by Res treatment. Res treatment began 4 weeks after ORCD and continued for 12 weeks. After 12 weeks, bone mineral density (BMD) and bone mineral content (BMC) were measured in the tibia and femur of each rat's right hind leg. Blood levels of bone turnover indicators such as deoxypyridinoline (Dpd), N-telopeptide of type I collagen (NTX I), alkaline phosphatase (ALP), and osteocalcin (OC), as well as receptor activator of nuclear factor kappa B (RANK) and osteoprotegerin (OPG) were assessed. RESULTS: ORCD significantly decreased BMD (P<0.01) and significantly increased bone resorption, manifested by increased RANK. In addition, it inhibited serum levels of OPG and OC. Res treatment after ORCD effectively increased serum levels of bone formation markers such as OPG and OC, compared with testisectomized rats (P<0.05). CONCLUSION: Res could ameliorate bone loss induced by male hypogonadism, possible via restoration of the normal balance between RANK and OPG.


Subject(s)
Hypogonadism , Osteoporosis , Rats , Male , Animals , Bone Density , Resveratrol/pharmacology , Osteoprotegerin/pharmacology , Bone Remodeling , RANK Ligand/pharmacology
2.
J Med Food ; 24(12): 1255-1263, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34704833

ABSTRACT

Ulcerative colitis is a chronic inflammation of the colonic mucosa. Gum Arabic (GA) has been reported to exert anti-inflammatory and antifibrotic activity. This study aimed to evaluate the effect of GA on disease activity in an experimental model of colitis. Dextran sodium sulfate (DSS) was used to induce colitis in C57BL/6 mice and the animals were then switched to normal drinking water to monitor recovery. Mice received 140 g/L GA before (pre-GA group) or after (post-GA group) induction of colitis. Disease activity and recovery were assessed by changes in body weight, disease activity index (DAI), and histological assessment. Gene expression of proinflammatory, anti-inflammatory, and fibrotic markers was measured in colonic tissues. Mice in the pre-GA group showed an increase in body weight, with no differences in DAI scores, during the recovery phase and had lower histological colitis scores than mice in the post-GA group, which showed higher DAI and histological scores during the recovery phase. During the recovery phase, mice in the pre-GA group showed increased expression of proinflammatory markers, while gene expression of the fibrotic markers, transforming growth factor ß1 (TGFß1) and procollagen I, was reduced. The reduced fibrotic marker expression was associated with reduced collagen staining and increased epithelial cell proliferation. Administration of GA had protective and alleviative effects on the severity of DSS-induced colitis, with a reduction in colonic fibrosis and TGFß1 expression. These data warrant further in vitro and in vivo investigations on the effect of GA on fibroblast activity.


Subject(s)
Colitis , Gum Arabic , Animals , Colitis/chemically induced , Colitis/drug therapy , Colitis/genetics , Colon/pathology , Dextran Sulfate , Dietary Supplements , Disease Models, Animal , Fibrosis , Mice , Mice, Inbred C57BL , Transforming Growth Factor beta1/genetics
3.
PLoS One ; 16(8): e0255701, 2021.
Article in English | MEDLINE | ID: mdl-34358244

ABSTRACT

Ovarian cancer (OC) is characterized by a high morbidity and mortality, highlighting a great need for a better understanding of biological mechanisms that affect OC progression and improving its early detection methods. This study investigates effects of prolactin (PRL) on ovarian cancer cells, analyzes PRL receptors (PRLR) in tissue micro arrays and relates PRLR expression to survival of ovarian cancer. A database, composed of transcript profiles from OC, was searched for PRLR expression and results were put in relation to survival. Expression of PRLR in OC tissue sections and OC cell lines SKOV3, OV2008 and OVSAHO was assessed using immunohistochemistry, western blots and quantitative real-time PCR. The biological function of PRLR was evaluated by proliferation, colony formation and wound healing assays. Levels of PRLR mRNA are related to survival; in epithelial OC a high PRLR mRNA expression is related to a shorter survival. Analysis of a tissue micro array consisting of 84 OC showed that 72% were positive for PRLR immuno-staining. PRLR staining tended to be higher in OC of high grade tumors compared to lower grades. PRLR mRNA and protein can further be detected in OC cell lines. Moreover, in vitro treatment with PRL significantly activated the JAK/STAT pathway. PRLR expression is associated with OC survivals. PRL and its receptor may play an onco-modulatory role and promote tumor aggressiveness in OC. Alternatively, increased PRLR levels may form a base for the development of PRLR antagonist or PRLR antagonist-drug conjugate to increase selective uptake of anti-cancer drugs.


Subject(s)
Carcinoma, Ovarian Epithelial/metabolism , Carcinoma, Ovarian Epithelial/mortality , Ovarian Neoplasms/metabolism , Ovarian Neoplasms/mortality , Prolactin/pharmacology , Receptors, Prolactin/metabolism , Signal Transduction/drug effects , Carcinoma, Ovarian Epithelial/pathology , Cell Movement/drug effects , Cell Proliferation/drug effects , Female , Humans , Immunohistochemistry , Kaplan-Meier Estimate , MCF-7 Cells , Ovarian Neoplasms/pathology , Phosphorylation/drug effects , Progression-Free Survival , RNA, Messenger/genetics , Real-Time Polymerase Chain Reaction , Receptors, Prolactin/genetics , Recombinant Proteins/pharmacology , STAT3 Transcription Factor/metabolism , STAT5 Transcription Factor/metabolism , Survival Rate
4.
Biology (Basel) ; 9(3)2020 Feb 27.
Article in English | MEDLINE | ID: mdl-32121009

ABSTRACT

One of the potential biomarkers for ovarian cancer patients is high serum level of prolactin (PRL), which is a growth factor that may promote tumor cell growth. The prolactin receptor (PRLR) and human cytomegalovirus (HCMV) proteins are frequently detected in ovarian tumor tissue specimens, but the potential impact of HCMV infection on the PRL system have so far not been investigated. In this study, HCMV's effects on PRL and PRLR expression were assessed in infected ovarian cancer cells (SKOV3) by PCR and Western blot techniques. The levels of both PRL and PRLR transcripts as well as the corresponding proteins were highly increased in HCMV-infected SKOV3 cells. Tissue specimens obtained from 10 patients with ovarian cancer demonstrated high expression of PRLR, HCMV-IE, and pp65 proteins. Extensive expression of PRLR was detected in all examined ovarian tumor tissue specimens except for one from a patient who had focal expression of PRLR and this patient was HCMV-negative in her tumor. In conclusion, PRL and PRLR were induced to high levels in HCMV-infected ovarian cancer cells and PRLR expression was extensively detected in HCMV-infected ovarian tissue specimens. Highly induced PRL and PRLR by HCMV infection may be of relevance for the oncomodulatory role of this virus in ovarian cancer.

5.
Earth Syst Environ ; 4(4): 797-811, 2020.
Article in English | MEDLINE | ID: mdl-34723076

ABSTRACT

Coronavirus disease (COVID-19), caused by acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a worldwide challenge effecting millions of people in more than 210 countries, including the Sultanate of Oman (Oman). Spatiotemporal analysis was adopted to explore the spatial patterns of the spread of COVID-19 during the period from 29th April to 30th June 2020. Our assessment was made using five geospatial techniques within a Geographical Information System (GIS) context, including a weighted mean centre (WMC), standard deviational ellipses, Moran's I autocorrelation coefficient, Getis-Ord General-G high/low clustering, and Getis-Ord G i ∗ statistic. The Moran's I-/G- statistics proved that COVID-19 cases in datasets (numbers of cases) were clustered throughout the study period. The Moran's I and Z scores were above the 2.25 threshold (a confidence level above 95%), ranging from 2274 cases on 29th April to 40,070 cases on 30th June 2020. The results of G i ∗ showed varying rates of infections, with a large spatial variability between the different wilayats (district). The epidemic situation in some wilayats, such as Mutrah, As-Seeb, and Bowsher in the Muscat Governorate, was more severe, with Z score higher than 5, and the current transmission still presents an increasing trend. This study indicated that the directional pattern of COVID-19 cases has moved from northeast to northwest and southwest, with the total impacted region increasing over time. Also, the results indicate that the rate of COVID-19 infections is higher in the most populated areas. The findings of this paper provide a solid basis for future study by investigating the most resolute hotspots in more detail and may help decision-makers identify targeted zones for alleviation plans. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s41748-020-00194-2.

6.
PLoS One ; 14(5): e0215831, 2019.
Article in English | MEDLINE | ID: mdl-31063493

ABSTRACT

Increasing evidence suggests that signaling through the prolactin/prolactin receptor axis is important for stimulation the growth of many cancers including glioblastoma multiforme, breast and ovarian carcinoma. Efficient inhibitors of signaling have previously been developed but their applicability as cancer drugs is limited by the short in vivo half-life. In this study, we show that a fusion protein, consisting of the prolactin receptor antagonist PrlRA and an albumin binding domain for half-life extension can be expressed as inclusion bodies in Escherichia coli and efficiently refolded and purified to homogeneity. The fusion protein was found to have strong affinity for the two intended targets: the prolactin receptor (KD = 2.3±0.2 nM) and mouse serum albumin (KD = 0.38±0.01 nM). Further investigation showed that it could efficiently prevent prolactin mediated phosphorylation of STAT5 at 100 nM concentration and above, similar to the PrlRA itself, suggesting a potential as drug for cancer therapy in the future. Complexion with HSA weakened the affinity for the receptor to 21±3 nM, however the ability to prevent phosphorylation of STAT5 was still prominent. Injection into rats showed a 100-fold higher concentration in blood after 24 h compared to PrlRA itself.


Subject(s)
Prolactin/pharmacology , Receptors, Prolactin/antagonists & inhibitors , STAT5 Transcription Factor/metabolism , Animals , Cell Line, Tumor , Half-Life , Humans , Male , Phosphorylation/drug effects , Prolactin/pharmacokinetics , Rats , Rats, Wistar , Recombinant Fusion Proteins/pharmacokinetics , Recombinant Fusion Proteins/pharmacology , Tissue Distribution
7.
Sci Rep ; 7: 42800, 2017 02 20.
Article in English | MEDLINE | ID: mdl-28216640

ABSTRACT

SOCS2 is a pleiotropic E3 ligase. Its deficiency is associated with gigantism and organismal lethality upon inflammatory challenge. However, mechanistic understanding of SOCS2 function is dismal due to our unawareness of its protein substrates. We performed a mass spectrometry based proteomic profiling upon SOCS2 depletion and yield quantitative data for ~4200 proteins. Through this screen we identify a novel target of SOCS2, the serine-threonine kinase NDR1. Over-expression of SOCS2 accelerates turnover, while its knockdown stabilizes, endogenous NDR1 protein. SOCS2 interacts with NDR1 and promotes its degradation through K48-linked ubiquitination. Functionally, over-expression of SOCS2 antagonizes NDR1-induced TNFα-stimulated NF-κB activity. Conversely, depletion of NDR1 rescues the effect of SOCS2-deficiency on TNFα-induced NF-κB transactivation. Using a SOCS2-/- mice model of colitis we show that SOCS2-deficiency is pro-inflammatory and negatively correlates with NDR1 and nuclear p65 levels. Lastly, we provide evidence to suggest that NDR1 acts as an oncogene in prostate cancer. To the best of our knowledge, this is the first report of an identified E3 ligase for NDR1. These results might explain how SOCS2-deficiency leads to hyper-activation of NF-κB and downstream pathological implications and posits that SOCS2 induced degradation of NDR1 may act as a switch in restricting TNFα-NF-κB pathway.


Subject(s)
Colitis/metabolism , NF-kappa B/metabolism , Prostatic Neoplasms/metabolism , Protein Serine-Threonine Kinases/chemistry , Proteomics/methods , Suppressor of Cytokine Signaling Proteins/metabolism , Animals , Cell Line, Tumor , Colitis/genetics , Disease Models, Animal , Enzyme Stability , Gene Expression Regulation , HEK293 Cells , Humans , Male , Mass Spectrometry , Mice , Protein Serine-Threonine Kinases/metabolism , Suppressor of Cytokine Signaling Proteins/deficiency , Transcriptional Activation , Tumor Necrosis Factor-alpha/metabolism , Ubiquitination
8.
Oncotarget ; 7(48): 79572-79583, 2016 Nov 29.
Article in English | MEDLINE | ID: mdl-27788487

ABSTRACT

Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in humans and is characterized with poor outcome. In this study, we investigated components of prolactin (Prl) system in cell models of GBM and in histological tissue sections obtained from GBM patients. Expression of Prolactin receptor (PrlR) was detected at high levels in U251-MG, at low levels in U87-MG and barely detectable in U373 cell lines and in 66% of brain tumor tissues from 32 GBM patients by immunohistochemical technique. In addition, stimulation of U251-MG and U87-MG cells but not U373 with Prl resulted in increased STAT5 phosphorylation and only in U251-MG cells with increased cellular invasion. Furthermore, STAT5 phosphorylation and cellular invasion induced in Prl stimulated cells were significantly reduced by using a Prl receptor antagonist that consists of Prl with four amino acid replacements. We conclude that Prl receptor is expressed at different levels in the majority of GBM tumors and that blocking of PrlR in U251-MG cells significantly reduce cellular invasion.


Subject(s)
Brain Neoplasms/metabolism , Cell Movement/drug effects , Glioblastoma/metabolism , Prolactin/pharmacology , Receptors, Prolactin/agonists , STAT5 Transcription Factor/metabolism , Antineoplastic Agents, Hormonal/pharmacology , Brain Neoplasms/drug therapy , Brain Neoplasms/pathology , Cell Line, Tumor , Dose-Response Relationship, Drug , Glioblastoma/drug therapy , Glioblastoma/pathology , Hormone Antagonists/pharmacology , Humans , Neoplasm Invasiveness , Phosphorylation , Receptors, Prolactin/antagonists & inhibitors , Receptors, Prolactin/metabolism , Signal Transduction/drug effects
9.
PLoS One ; 11(1): e0146653, 2016.
Article in English | MEDLINE | ID: mdl-26765535

ABSTRACT

Pulmonary lymphangioleiomyomatosis (LAM) is a rare lung disease caused by mutations in the tumor suppressor genes encoding Tuberous Sclerosis Complex (TSC) 1 and TSC2. The protein product of the TSC2 gene is a well-known suppressor of the mTOR pathway. Emerging evidence suggests that the pituitary hormone prolactin (Prl) has both endocrine and paracrine modes of action. Here, we have investigated components of the Prl system in models for LAM. In a TSC2 (+/-) mouse sarcoma cell line, down-regulation of TSC2 using siRNA resulted in increased levels of the Prl receptor. In human LAM cells, the Prl receptor is detectable by immunohistochemistry, and the expression of Prl in these cells stimulates STAT3 and Erk phosphorylation, as well as proliferation. A high affinity Prl receptor antagonist consisting of Prl with four amino acid substitutions reduced phosphorylation of STAT3 and Erk. Antagonist treatment further reduced the proliferative and invasive properties of LAM cells. In histological sections from LAM patients, Prl receptor immuno reactivity was observed. We conclude that the Prl receptor is expressed in LAM, and that loss of TSC2 increases Prl receptor levels. It is proposed that Prl exerts growth-stimulatory effects on LAM cells, and that antagonizing the Prl receptor can block such effects.


Subject(s)
Lymphangioleiomyomatosis/metabolism , Receptors, Prolactin/metabolism , Animals , Cell Line, Tumor , Cells, Cultured , Extracellular Signal-Regulated MAP Kinases/metabolism , Humans , Lymphangioleiomyomatosis/genetics , Mice , Receptors, Prolactin/genetics , STAT3 Transcription Factor/metabolism , Tuberous Sclerosis Complex 2 Protein , Tumor Suppressor Proteins/genetics
10.
Horm Mol Biol Clin Investig ; 26(1): 67-76, 2016 Apr 01.
Article in English | MEDLINE | ID: mdl-26562042

ABSTRACT

BACKGROUND: Diabetes type 1 is characterized by the failure of beta cells to produce insulin. Suppressor of cytokine signaling (SOCS) proteins are important regulators of the Janus kinase/signal transducer and activator of transcription (JAK-STAT) pathway. Previous studies have shown that GH can prevent the development of type I diabetes in mice and that SOCS2 deficiency mimics a state of increased GH sensitivity. METHODOLOGY: The elevated sensitivity of SOCS2-/- mice to GH and possibly to PRL was the rationale to analyze the effects of multiple low dose streptozotocin (MLDSTZ)-induced diabetes in SOCS2-/- mice. RESULTS: We show that 6-month-old SOCS2-/- mice, but not 2-month-old mice, were less sensitive to MLDSTZ-induced diabetes, compared to controls. MLDSTZ treatment induced glucose intolerance in both SOCS2+/+ and SOCS2-/- mice, as shown by glucose tolerance tests, with SOCS2+/+ mice showing a more marked intolerance, compared to SOCS2-/- mice. Furthermore, insulin tolerance tests showed that the SOCS2-/- mice have an improved hypoglycemic response to exogenous insulin, compared to SOCS2+/+ mice. Moreover, in isolated islets, lipotoxic effects on insulin release could partly be overcome by ligands, which bind to GH or PRL receptors. CONCLUSION: Knockdown of SOCS2 makes mice less sensitive to MLDSTZ. These results are consistent with the proposal that elimination of SOCS2 in pancreatic islets creates a state of ß-cell hypersensitivity to GH/PRL that mimics events in pregnancy, and which is protective against MLDSTZ-induced type I diabetes in mice. SOCS2-dependent control of ß-cell survival may be of relevance to islet regeneration and survival in transplantation.


Subject(s)
Diabetes Mellitus, Experimental/genetics , Diabetes Mellitus, Type 1/genetics , Gene Deletion , Suppressor of Cytokine Signaling Proteins/metabolism , Animals , Cells, Cultured , Diabetes Mellitus, Experimental/metabolism , Diabetes Mellitus, Type 1/metabolism , Glucose/metabolism , Growth Hormone/pharmacology , Insulin/metabolism , Insulin-Secreting Cells/drug effects , Insulin-Secreting Cells/metabolism , Mice , Mice, Inbred C57BL , Prolactin/pharmacology , Streptozocin/toxicity , Suppressor of Cytokine Signaling Proteins/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...